18 March 2021 in PLOS Pathogens
Arteriviruses are enveloped positive-strand RNA viruses that assemble and egress using the host cell’s exocytic pathway. In previous studies, we demonstrated that most arteriviruses use a unique -2 ribosomal frameshifting mechanism to produce a C-terminally modified variant of their nonstructural protein 2 (nsp2). Like full-length nsp2, the N-terminal domain of this frameshift product, nsp2TF, contains a papain-like protease (PLP2) that has deubiquitinating (DUB) activity, in addition to its role in proteolytic processing of replicase polyproteins. In cells infected with porcine reproductive and respiratory syndrome virus (PRRSV), nsp2TF localizes to compartments of the exocytic pathway, specifically endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and Golgi complex. Here, we show that nsp2TF interacts with the two major viral envelope proteins, the GP5 glycoprotein and membrane (M) protein, which drive the key process of arterivirus assembly and budding. The PRRSV GP5 and M proteins were found to be poly-ubiquitinated, both in an expression system and in cells infected with an nsp2TF-deficient mutant virus. In contrast, ubiquitinated GP5 and M proteins did not accumulate in cells infected with the wild-type, nsp2TF-expressing virus. Further analysis implicated the DUB activity of the nsp2TF PLP2 domain in deconjugation of ubiquitin from GP5/M proteins, thus antagonizing proteasomal degradation of these key viral structural proteins. Our findings suggest that nsp2TF is targeted to the exocytic pathway to reduce proteasome-driven turnover of GP5/M proteins, thus promoting the formation of GP5-M dimers that are critical for arterivirus assembly.
21 October 2011 in Immunological Investigations
The open reading frame (ORF) 5 of porcine reproductive and respiratory syndrome virus (PRRSV) encodes a major envelope glycoprotein designated GP5. The GP5 protein is a candidate for vaccinating against PRRSV infection. In this study, recombinant plasmids bearing the PRRSV GP5 gene (pVAX-GP5) or the porcine interleukin 15 gene (pVAX-IL15) were generated. Mice were vaccinated with these gene constructs singularly or in combination, and subsequent humoral and cellular immune responses were evaluated. Proliferation assays showed that the number of T lymphocytes in the peripheral blood and spleens of treated mice were elevated by pVAX-GP5 and significantly enhanced by combination therapy involving pVAX-IL15. Flow cytometry data showed that the numbers of CD4+ and CD8+ T cells were also higher in treated mice. Both pVAX-GP5 treatment alone and in combination with pVAX-IL15 resulted in elevated antibody levels as demonstrated by indirect ELISA. The pVAX-IL15 gene construct served as a molecular adjuvant in conjunction with the pVAX-GP5 to enhance the immune responses where intermediate doses of pVAX-IL15 were most effective.